Motif Bio PLC Result of AGM (0789A)

TIDMMTFB

RNS Number : 0789A

Motif Bio PLC

02 June 2016

2 June 2016

Motif Bio plc

("Motif Bio" or the "Company")

Result of Annual General Meeting

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

For further information please contact:

 
 Motif Bio plc                                                   info@motifbio.com 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited (NOMAD 
  & BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                               +44 (0)20 3829 5000 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/ David 
  Hignell 
  John Howes/ Rob Rees (Broking)                               +44 (0)20 3861 6625 
 Walbrook PR Ltd. (FINANCIAL        +44 (0)20 7933 8780 or motifbio@walbrookpr.com 
  PR & IR)                                                Mob: +44 (0)7980 541 893 
  Paul McManus                                            Mob: +44 (0)7900 608 002 
  Mike Wort

Notes to Editors:

Motif Bio is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif Bio please visit www.motifbio.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGBSGDLUXGBGLD

(END) Dow Jones Newswires

June 02, 2016 10:37 ET (14:37 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024